HIGHER-RISK MYELODYSPLASTIC SYNDROME
Clinical trials for HIGHER-RISK MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new HIGHER-RISK MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for HIGHER-RISK MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for blood cancer patients: experimental drug CCS1477 enters human trials
Disease control Recruiting nowThis study tests a new drug called CCS1477 in people with advanced blood cancers like leukemia, lymphoma, and multiple myeloma that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. About 250 participants will receiv…
Matched conditions: HIGHER-RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: CellCentric Ltd. • Aim: Disease control
Last updated May 26, 2026 10:48 UTC
-
New hope for high-risk MDS: phase 3 trial of lisaftoclax combo launches globally
Disease control Recruiting nowThis study tests whether adding the experimental drug lisaftoclax to standard chemotherapy (azacitidine) helps people with newly diagnosed, higher-risk myelodysplastic syndrome (a serious blood cancer) live longer. About 490 adults worldwide will be randomly assigned to receive e…
Matched conditions: HIGHER-RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE3 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated May 26, 2026 10:41 UTC
-
New antibody GEN3018 enters first human trials for relapsed leukemia and MDS
Disease control Recruiting nowThis early-stage trial tests a new antibody drug called GEN3018 in people whose acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS) has returned or stopped responding to treatment. The main goal is to check safety and find the right dose for future studies.…
Matched conditions: HIGHER-RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated May 20, 2026 11:54 UTC